SomaLogic, Inc.

CM Life Sciences III Inc. (Nasdaq: CMII) is a life sciences-focused special purpose acquisition company that completed its initial public offering in 2021, sponsored by CM Life Sciences. In early 2021, CMII announced a definitive merger agreement with SomaLogic, Inc., a proteomics technology company specializing in aptamer-based protein measurement platforms. This 10-Q, filed with the SEC on May 24, 2021, captures the SPAC's financial position during the period between announcement and the pending business combination. The transaction subsequently closed in September 2021, with the combined company trading under the SomaLogic name on Nasdaq. Sign up at SpacDesk for full filing history, timeline data, and analytics on CMII and hundreds of other SPAC transactions.